Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: vical + 654 + vaccine  Related to the article below (Last Update: 8/5/2008)

Vical Reports Second Quarter and First Six Months 2008 Financial ...
PR Newswire (press release), NY - 35 minutes ago
5 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the quarter and six months ended June 30, 2008. ...VICL - TYO3:4563

Desastres.org
Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines ...
FOXBusiness - Jul 17, 2008
No significant safety issues were observed at any of the Vical vaccine doses tested. These results support further development of Vaxfectin(R)-formulated ...
Biojector(R)2000 Data Presented in Vical's Pandemic Influenza DNA ... MarketWatch
Vical reports breakthrough with bird flu vaccine FierceBioResearcher
Vical says Phase 1 clinical trial of Vaxfectin DNA vaccine ... RTT News
WorldPoultry.net
all 41 news articles »  VICL - OTC:CMTX
Vical Receives $1 Million Milestone Payment From AnGes MG for ...
MarketWatch - Jul 22, 2008
Vical received an initial upfront payment of $1.0 million under an exclusive license agreement in 2005, and further advancement may lead to additional ...
Vical Receives $1 Million Milestone Payment From AnGes MG for ... Biloxi Sun Herald
all 11 news articles »  TYO3:4563 - VICL
Vical Announces News Release and Conference Call Schedule for ...
Earthtimes (press release), UK - Jul 29, 2008
SAN DIEGO , July 29 -- Vical Incorporated (Nasdaq: VICL) today announced that the company will report financial results for the three months and six months ...VICL
Vical Takes New Tack With Bird-Flu Vaccine
Wall Street Journal - Jul 16, 2008
Vical Inc. said its Phase 1, or early-stage, clinical trial tested several doses against a placebo, or dummy shot, in 100 healthy adults and safely sparked ...VICL
Vical says its DNA vaccine for bird flu works
Reuters - Jul 16, 2008
The Phase I clinical trial, meant to demonstrate the vaccine is safe, was continuing, Vical said in a statement. "The preliminary results from this Phase 1 ...VICL
Vical (VICL) newly added by Princeton Capital Management Inc
Mffais.com, CA - Jul 25, 2008
LONG BEACH (Mffais.com) - Princeton Capital Management Inc added the Vical (VICL) company to their portfolio, by buying 20000 shares as shown by filings ...VICL
Vical (VICL) holdings reduced by Temasek Holdings Private Ltd
Mffais.com, CA - Jul 23, 2008
LONG BEACH (Mffais.com) - Temasek Holdings Private Ltd sold -4980079 (-50.00 %) of their shares in Vical (VICL), bringing their current holdings to 4980079 ...
Vical (VICL) completely dumped by Crown Capital Management Mffais.com
all 2 news articles »  VICL
Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic ...
SunHerald.com, MS - Jul 14, 2008
By Vical Incorporated Vical Incorporated (Nasdaq: VICL) today announced the scheduled presentation of preliminary human safety and immunogenicity data from ...VICL
Vical Sees Potential in Influenza DNA Vaccines
FDA news (subscription), VA - Jul 22, 2008
Vical has achieved promising results with its Phase I trial of its Vaxfectin-formulated DNA vaccine for the treatment of H5N1 influenza. ...VICL
Source: Google News

Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ cytotoxic T … -
SL Epstein, A Stack, JA Misplon, CY Lo, H … - International Immunology, 2000 - Jpn Soc Immunol
... PRNP obtained from Dr Suezanne Parker, Vical, under a ... 29:654.[Medline]; Sonoguchi,
T., Naito, H., Hara, M ... Vaccine 16:1748.[Medline]; Apasov, S. and Sitkovsky, M ...

Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 … -
CW Lin, JY Lee, YP Tsao, CP Shen, HC Lai, SL Chen - Int J Cancer, 2002 - doi.wiley.com
... Hence, the potency of rLM-E7 as a therapeutic vaccine for cervical cancer is the
result of the induction E7-specific cell-mediated immunity by L. monocytogenes ...

Multiprotein HIV Type 1 Clade B DNA/MVA Vaccine: Construction, Safety, and Immunogenicity in … -
JM Smith, RR Amara, HM McClure, M Patel, S Sharma, … - AIDS Research and Human Retroviruses, 2004 - liebertonline.com
... 654?665 ?Mary Ann Liebert, Inc. ... All vaccine inserts were cloned into both pGA1
and pGA2. The pGA2/JS2 plasmid was produced by Vical, Inc. ...

… anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum … -
SL Fanning, B Czesny, M Sedegah, DJ Carucci, GJ … - Vaccine, 2003 - Elsevier
... using the mammalian expression vector, VR1020 (Vical, San Diego ... Modification of the
VR1020 DNA vaccine plasmid. ... anchor sequence of Pfs25 (577?654 bp) flanked ...

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion … -
JG Gomez-Gutierrez, KG Elpek, R Montes de Oca-Luna … - Cancer Immunology, Immunotherapy, 2007 - Springer
... This vaccine is shown to be highly eYcient to prevent carcinoma in situ development ...
not treat patients with existing HPV infection or with cer- vical carcinoma ...

… Effect of Vaxfectin on the Ability of a Japanese Encephalitis DNA Vaccine to Induce Neutralizing … -
C Nukuzuma, N Ajiro, CJ Wheeler, E Konishi - Viral Immunology, 2003 - liebertonline.com
... 2 Department of Chemistry, Vical Inc., San Diego, California. ... 7-10-2 Tomogaoka,
Suma-ku Kobe 654-0142, Japan ... VAXFECTIN AND JAPANESE ENCEPHALITIS DNA VACCINE ...

… Human Esophageal Cancer Cell Challenge by a Novel HPV16-E6/E7 Fusion Protein Based-Vaccine in a Hu- … -
Y Lu, Z Zhang, Q Liu, B Liu, X Song, M Wang, X … - Biological & Pharmaceutical Bulletin, 2007 - J-STAGE
... protein vaccine was able to ef- fectively stimulate the generation of HPV16
E6/E7-specific CTL response to HPV16-positive esophageal cancer and cer- vical ...

Intradermal DNA immunization by using jet-injectors in mice and monkeys -
J Haensler, C Verdelet, V Sanchez, Y Girerd- … - Vaccine, 1999 - Elsevier
... XbaI digested VR1012 vector provided by Dr. P. Hobart, Vical, San Diego ... the monkeys
had received three injections of inactivated polio vaccine (Pasteur M?rieux ...

Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting … -
Y Lu, K Raviprakash, IC Leao, PR Chikhlikar, D … - Vaccine, 2003 - Elsevier
... the application of the LAMP technology for humoral immunity to a DNA vaccine. ... The
amplicon was inserted into pVR1012 (Vical, San Diego, CA) between the SalI ...

DNA vaccines against chronic lung infections by Pseudomonas aeruginosa -
J Staczek, LB Gilleland, HC Heyde, HE Gilleland - FEMS Immunology and Medical Microbiology, 2003 - Blackwell Synergy
... The F/I vaccine [23] uses the eukaryotic expression plasmid pVR1020 (Vical, San
Diego, CA ... However, the observation that the F/I vaccine does not ... 14, 643?654. ...

Source: Google Scholar

Vical Reaches Initial Enrollment Milestone In Phase 2 Trial Of DNA Vaccine Against CMV
Vical Incorporated (Nasdaq: VICL) today announced the enrollment of the 20th hematopoietic stem cell transplant recipient in the company's Phase 2 trial of a DNA vaccine against cytomegalovirus (CMV). After the 20th recipient's two-month follow-up visit, an independent data safety monitoring board will conduct an interim evaluation of safety data for all subjects enrolled in the trial.

"We are pleased that recent protocol amendments have accelerated patient enrollment in our CMV vaccine trial," said Ronald B. Moss, M.D., Vice President of Clinical Development at Vical, "and we hope to sustain the momentum by continuing to enroll additional patients as safety data are being collected and evaluated. Our novel immunotherapeutic vaccine may address the serious healthcare problem of CMV reactivation for transplant patients, and could eventually be useful in preventing birth defects caused by CMV infection of pregnant women."
The double-blind, placebo-controlled Phase 2 trial was designed to compare safety of the vaccine against placebo in approximately 80 matched, related donor/recipient pairs scheduled for hematopoietic stem cell transplants. Subsequent protocol amendments intended to provide additional scientific insights and speed up trial enrollment include a more convenient donor vaccination schedule and vaccination of recipients only. Because most recipients are expected to face a natural viral challenge as pre-existing CMV infection reactivates under immunosuppression, the primary efficacy endpoint is the occurrence rate of clinically significant CMV levels in patients receiving vaccine compared with patients receiving placebo. Other important endpoints include immune responses against the specific CMV features targeted by the vaccine.

About CMV

CMV is a herpes virus that infects more than half of all adults in the United States by age 40, and is even more widespread in developing countries. While a healthy immune system typically protects an infected person against CMV disease, it rarely succeeds in completely eliminating the infection, and those whose immune systems are not fully functional are at high risk of CMV proliferation, potentially leading to severe illness or death. These include transplant patients who take immunosuppressive drugs, and fetuses and newborns of mothers who first become infected during pregnancy.

CMV infection affects 30 to 60 percent of the patients undergoing various transplant procedures, causing transplant rejection, serious illness and even death if untreated. Expensive antiviral drug therapy is used to control the disease, but does not eliminate the infection. Congenital CMV infection affects one out of every hundred infants, and causes severe consequences in about 3,600 infants and death in about 400 each year in the United States.

There is no approved vaccine against CMV. Vaccine approaches that result in predominantly antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.
About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether the company will initiate the Phase 2 trial at leading transplant centers and successfully enroll 80 matched, related stem cell transplant donor/recipient pairs in a timely manner, if at all; whether the CMV vaccine will achieve the safety and efficacy endpoints in the Phase 2 trial for stem cell transplant donors and recipients; whether the company will expand development of a CMV vaccine to address prevention of congenital disease; whether the vaccine will induce both antibody and cellular immune responses; whether the vaccine will prevent clinically significant CMV levels; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Vical Incorporated
http://www.vical.com
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.